Revolution Medicines RVMDW

NASDAQ RVMDW
$7.11 -1.03 (-12.70%)
As of: Nov 16, 2026 · 3:31 PM EST

Revolution Medicines (RVMDW) stock price is $7.11, down 12.70% on the day, as of Nov 16, 2026. It has a market cap of $35.75Bn, and is classified in the Pharmaceuticals industry (Healthcare sector).

Key Stats
Market Cap35.75 Bn
P/E-19.11
FCF (Yr)-913.73 Mn
ROA (Yr)-45.98
EV to EBIT-14.38
Net Income (Yr)-1.13 Bn
Enterprise Value24.23 Bn
Add ratio to table…

About

Revolution Medicines, Inc. was founded in October 2014 as a Delaware corporation. The company is a clinical stage precision oncology enterprise dedicated to discovering and developing novel targeted therapies for cancers driven by RAS mutations. Its scientific approach centers on a proprietary tri complex technology platform that enables the design of small molecules capable of binding to unconventional sites on the active GTP bound form of RAS known as RAS(ON). The…

Read more ↓
Sector: Healthcare Sector rationale Revolution Medicines is a clinical-stage biotechnology company focused on discovering and developing targeted therapies for cancers driven by RAS mutations. Its core business involves the development of small molecule inhibitors (e.g., daraxonrasib) and the management of clinical trials for indications like pancreatic and lung cancer, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector. Industry: Pharmaceuticals Pharmaceuticals Primary Revolution Medicines is a clinical-stage company developing small-molecule RAS(ON) inhibitors for cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. Its core business is the discovery and development of branded prescription pharmaceuticals based on its proprietary tri complex technology platform. Classified using BQ-MICS CIK: 0001628171
Bull & bear

Investment Thesis

▲ Bull case
  • Revolution Medicines has achieved a transformative breakthrough with its pancreatic cancer drug daraxonrasib, demonstrating unprecedented efficacy in a Phase 3 trial that nearly doubles overall survival to 13.2 months versus 6.7 months for chemotherapy and reduces the risk of death by 60%, positioning the drug as a potential new standard of care in a disease with historically dismal outcomes and establishing a clear path to rapid FDA approval through the Commissioner's National Priority Voucher program, which enables expedited review within months rather than the typical timeline. The drug's mechanism as a first-in-class RAS(ON) inhibitor targeting the prevalent G12RAS mutation—found in approximately 90% of pancreatic cancers—creates a durable competitive advantage by addressing a fundamental driver of tumor growth that prior therapies failed to inhibit effectively, with early data showing tumor control duration more than doubling (7.3 months vs 3.5 months) and tumor shrinkage rates tripling (33.2% vs 11.8%) in biomarker-selected patients, supporting potential expansion into earlier lines of therapy and combination regimens that could significantly broaden its addressable market. Despite high rates of manageable side effects like rash (occurring in 86.3% of patients), the drug demonstrates a superior overall safety profile compared to chemotherapy, with severe or life-threatening adverse events occurring in 43.6% of daraxonrasib-treated patients versus 57.5% in the chemotherapy arm, and minimal treatment discontinuation due to side effects (1.2% vs 11.2%), indicating that tolerability challenges are unlikely to impede widespread adoption given the magnitude of clinical benefit. The commercial opportunity is substantial and underappreciated, with pancreatic cancer affecting approximately 68,000 Americans annually and Revolution Medicines already advancing daraxonrasib into first-line and combination trials, which—if successful—could capture a large portion of the metastatic pancreatic cancer market where current therapies offer minimal benefit, potentially supporting peak sales well into the billions of dollars and justifying the company's current market valuation of over $26 billion as a reflection of long-term value creation rather than speculative takeover premiums. Revolution Medicines' strategic focus on accelerating approval and commercial launch—rather than pursuing acquisition discussions—signals confidence in the drug's standalone value and de-risks the investment thesis by reducing dependence on M&A outcomes, with management prioritizing preparation for FDA submission and global rollout, thereby aligning corporate execution with the transformative clinical data already in hand.

Product and Service Breakdown of Revenue (2022)

History
Peer percentiles

How Revolution Medicines ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −19.8xMedian 17.0x 77th
  • P/FCFNegative free cash flow −25.9xMedian 19.0x 77th
  • P/Operating cash flowNegative operating cash flow −26.0xMedian 16.4x 78th
  • P/S 189xMedian 8.38x 11th
  • P/B 15.5xMedian 2.04x 7th
  • P/Tangible book 15.9xMedian 2.31x 8th
  • EV/EBITDANegative EBITDA −19.9xMedian 14.6x 72nd
  • EV/EBITNegative EBIT −19.9xMedian 18.4x 74th
  • EV/Revenue 170xMedian 6.34x 10th
  • EV/FCFNegative free cash flow −23.3xMedian 23.4x 73rd
  • EV/Operating cash flowNegative operating cash flow −23.5xMedian 19.3x 73rd
  • PEG (3Y EPS CAGR)Negative earnings 0.47Median 0.43 Not meaningful —
Peer group

Peer Comparison

Companies in the Pharmaceuticals
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,276.89 Bn46.3014.7749.50 Bn
2 JNJ Johnson & Johnson 681.31 Bn42.336.8644.65 Bn
3 ABBV AbbVie Inc. 520.63 Bn50.347.8980.90 Bn
4 MRK Merck & Co., Inc. 357.22 Bn145.635.3053.78 Bn
5 NVS Novartis Ag 310.90 Bn17.915.08-
6 AZN Astrazeneca Plc 285.12 Bn25.854.80-5.53 Bn
7 AMGN Amgen Inc 250.23 Bn26.656.4354.01 Bn
8 RVMD Revolution Medicines, Inc. 35.75 Bn-19.11180.980.01 Bn